Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$21.64 +0.9%	$23.77	$14.97 ▼ $26.58	$2.62B	0.66	1.12 million shs	687,432 shs
PRTA Prothena	$6.47 +2.4%	$6.46	$4.32 ▼ $25.42	$340.19M	0.01	796,589 shs	636,811 shs
PTGX Protagonist Therapeutics	$51.20 +1.0%	$49.27	$32.50 ▼ $60.60	$3.14B	2.26	843,674 shs	339,485 shs
STSA Satsuma Pharmaceuticals	$1.10	$1.08	$0.59 ▼ $8.08	$36.47M	0.1	701,788 shs	N/A
SYRS Syros Pharmaceuticals	$0.03 +2.0%	$0.03	$0.02 ▼ $6.93	$673K	1.31	8.06 million shs	44,922 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	+0.89%	-1.14%	-13.13%	-6.20%	+41.35%
PRTA Prothena	+2.37%	+4.69%	+33.95%	-40.42%	-67.76%
PTGX Protagonist Therapeutics	+1.01%	-7.28%	+0.27%	+15.21%	+48.41%
STSA Satsuma Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
SYRS Syros Pharmaceuticals	+2.03%	-13.45%	-3.09%	+5.46%	-99.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.9207 of 5 stars	3.6	1.0	0.0	3.9	3.2	3.3	3.8
PRTA Prothena	2.7784 of 5 stars	4.2	2.0	0.0	0.0	0.0	1.7	1.3
PTGX Protagonist Therapeutics	2.0808 of 5 stars	3.5	1.0	0.0	0.0	2.3	2.5	0.0
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	4.3564 of 5 stars	3.1	5.0	0.0	4.3	1.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.25	Buy	$32.83	51.73% Upside
PRTA Prothena	2.33	Hold	$31.50	386.86% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	29.10% Upside
STSA Satsuma Pharmaceuticals	0.00	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	2.20	Hold	$3.33	13,180.21% Upside

Current Analyst Ratings Breakdown

Latest PRTA, PTGX, STSA, SYRS, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/27/2025	PRTA Prothena	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$110.00 ➝ $81.00
5/27/2025	PRTA Prothena	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$78.00 ➝ $29.00
5/27/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
5/27/2025	PRTA Prothena	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00
5/27/2025	PRTA Prothena	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/27/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $14.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$491.73M	5.37	$2.47 per share	8.77	$6.10 per share	3.55
PRTA Prothena	$135.16M	2.58	N/A	N/A	$9.05 per share	0.71
PTGX Protagonist Therapeutics	$434.43M	7.30	$4.56 per share	11.22	$11.33 per share	4.52
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
SYRS Syros Pharmaceuticals	$386K	1.74	N/A	N/A	$0.79 per share	0.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.57	13.78	10.16	0.87	36.91%	42.45%	36.59%	8/6/2025 (Estimated)
PRTA Prothena	-$122.31M	-$2.08	0.00	N/A	N/A	-79.94%	-21.61%	-19.32%	8/6/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	67.59	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)
STSA Satsuma Pharmaceuticals	-$70.06M	-$2.01	N/A	N/A	N/A	N/A	-115.24%	-102.26%	N/A
SYRS Syros Pharmaceuticals	-$164.57M	-$3.03	N/A	N/A	N/A	N/A	-3,369.56%	-97.04%	7/29/2025 (Estimated)

Latest PRTA, PTGX, STSA, SYRS, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.14	5.96
PRTA Prothena	N/A	9.00	9.00
PTGX Protagonist Therapeutics	N/A	17.25	17.26
STSA Satsuma Pharmaceuticals	N/A	7.44	7.44
SYRS Syros Pharmaceuticals	N/A	2.25	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
PRTA Prothena	97.08%
PTGX Protagonist Therapeutics	98.63%
STSA Satsuma Pharmaceuticals	93.26%
SYRS Syros Pharmaceuticals	91.47%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
PRTA Prothena	9.20%
PTGX Protagonist Therapeutics	4.90%
STSA Satsuma Pharmaceuticals	31.20%
SYRS Syros Pharmaceuticals	12.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	121.97 million	109.29 million	Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable
STSA Satsuma Pharmaceuticals	21	33.15 million	22.81 million	Not Optionable
SYRS Syros Pharmaceuticals	120	26.83 million	23.54 million	Optionable

PRTA, PTGX, STSA, SYRS, and CPRX Headlines

Recent News About These Companies

Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $3.33

June 29, 2025 | americanbankingnews.com

Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals

April 15, 2025 | msn.com

Syros Pharmaceuticals trading resumes

March 1, 2025 | markets.businessinsider.com

Syros Pharmaceuticals Plans to Wind Down Operations

March 1, 2025 | marketwatch.com

Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock

March 1, 2025 | markets.businessinsider.com

Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

February 28, 2025 | businesswire.com

Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline

January 29, 2025 | msn.com

Syros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?

January 18, 2025 | bovnews.comB

What’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?

January 16, 2025 | bovnews.comB

SYRS’s Latest Surge: What’s Behind the Spike?

January 6, 2025 | bovnews.comB

The SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines Again

January 2, 2025 | bovnews.comB

Analysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?

December 31, 2024 | bovnews.comB

Syros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It Appears

December 27, 2024 | bovnews.comB

Syros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes Revealed

December 26, 2024 | bovnews.comB

What’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?

December 14, 2024 | bovnews.comB

Syros Pharmaceuticals Inc (SYRS) Stock Settles at $0.24: What’s Contributing to This Price Point?

December 7, 2024 | bovnews.comB

Why Did Syros Pharmaceuticals Inc (SYRS) Stock Plunge -1.67% Last Week?

December 5, 2024 | bovnews.comB

Nancy A. Simonian Sells 37,070 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Stock

December 5, 2024 | insidertrades.com

Syros Pharmaceuticals Inc (SYRS) Stock Rated Buy by H.C. Wainwright

December 2, 2024 | bovnews.comB

Why Is Syros Pharmaceuticals Inc (SYRS) Stock Lagging Behind -84.72% from Its 50-Day SMA?

November 29, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA, PTGX, STSA, SYRS, and CPRX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$21.64 +0.19 (+0.89%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$21.35 -0.29 (-1.34%)

As of 07/3/2025 04:59 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Prothena NASDAQ:PRTA

$6.47 +0.15 (+2.37%)

Closing price 07/3/2025 03:46 PM Eastern

Extended Trading

$6.41 -0.06 (-0.94%)

As of 07/3/2025 04:52 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Protagonist Therapeutics NASDAQ:PTGX

$51.20 +0.51 (+1.01%)

Closing price 07/3/2025 02:41 PM Eastern

Extended Trading

$51.18 -0.03 (-0.05%)

As of 07/3/2025 04:20 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Satsuma Pharmaceuticals NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Syros Pharmaceuticals NASDAQ:SYRS

$0.03 +0.00 (+2.03%)

As of 07/3/2025 12:37 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time